Bain Capital has agreed to acquire UK vitamin and supplements manufacturer Vitabiotics, in a deal that is reportedly worth around £900m.
The transaction covers Vitabiotics’ UK operations and the wider VB Group, including Meyer Organics in India and operations in Africa, including VB Egypt and is set to accelerate the company’s international expansion across key vitamins, minerals and supplements (VMS) markets.
A British health staple
Vitabiotics has grown into one of the UK’s best-known independent supplement businesses, with brands including Pregnacare, Perfectil, Wellman, Wellwoman, Osteocare and the Ultra range.
Founded in 1971 by Professor Kartar Lalvani OBE, it has grown into a British health powerhouse found in nearly every local pharmacy and supermarket.
The company exports to more than 70 countries and, according to previously published reports, generated around £275m in sales in its 2025 financial year.
The acquisition will see Bain Capital’s Asia Private Equity team lead the investment, supported by the firm’s wider global platform.
The private equity group said that its expertise and local market knowledge in India would help Vitabiotics strengthen its presence in markets including India, China, the Middle East and North Africa, while continuing to expand internationally.
For the nutraceutical industry, the deal highlights the growing strategic importance of established consumer health brands with a combination of scientific positioning, strong consumer recognition and international distribution networks.
UK will remain "central" to the brand
Vitabiotics said the UK would remain central to its brand, innovation and category leadership, with no immediate changes planned to day-to-day operations.
Investment priorities are expected to include digital capabilities, e-commerce, international distribution, supply chain resilience and new product development.
The company has also emphasised its manufacturing capabilities and science-led approach as it expands.
Vitabiotics also stated that the vast majority of its products are manufactured in the UK to GMP standards, but it also uses facilities in France, Germany and Switzerland for selected products.
Its portfolio spans products targeted at specific life stages and health needs, including pregnancy, men's and women's health, children's nutrition, healthy ageing and beauty.
Tej Lalvani, Vitabiotics’ Group CEO, said the deal represented an opportunity to “accelerate” international expansion and innovation while retaining the values that underpin the business.
"This marks a defining moment in Vitabiotics' journey... this direction is not about changing who we are; it is about accelerating what we can become."
With Bain Capital’s global expertise and investment behind us, we have a unique opportunity to expand internationally, accelerate our innovation and take our trusted brands to millions more consumers, while staying true to the science, quality and values that have defined Vitabiotics for more than 55 years.
His father and founder of the company, Professor Kartar Lalvani, will become Chairman Emeritus following completion of the transaction.
The acquisition marks a significant change in ownership for the 55-year-old business, but the strategic direction outlined by both parties points towards further internationalisation of Vitabiotics’ established VMS brands rather than an immediate shift in its UK operations.
